ArriVent BioPharma, Inc. filings document a Nasdaq-listed clinical-stage oncology company with common stock registered under the Exchange Act. Its Form 8-K reports cover financial results, Regulation FD disclosures, clinical and preclinical program announcements, conference presentations, IND-related updates, material-event disclosures, and exhibits tied to press releases.
Proxy materials describe stockholder voting matters, board elections, auditor ratification, annual meeting procedures, and governance information. The filing record also reflects capital-structure disclosures, emerging growth company status, material agreements, and risk-oriented disclosures associated with ArriVent's firmonertinib program and antibody-drug conjugate pipeline.
ArriVent BioPharma, Inc. (AVBP) is the issuer in a Schedule 13G reporting that Vivo Opportunity, LLC may be deemed to beneficially own an aggregate of 2,472,701 common shares, or 5.0% of the class. The aggregate consists of 1,514,446 shares held of record by Vivo Opportunity Fund Holdings, L.P., 176,752 by Vivo Opportunity Co-Invest, L.P., and 781,503 by Vivo Opportunity Co-Invest (Cycle 3), L.P.; Vivo Opportunity, LLC is their general partner. The three partnerships report 3.1%, 0.3%, and 1.6%, respectively.
Separately, Vivo Opportunity Cayman, LLC may be deemed to beneficially own 152,971 shares held of record by Vivo Opportunity Cayman Fund, L.P.; each reports 0.3%, and the Cayman LLC is the fund's general partner. The reported percentages are based on 49,307,729 ArriVent common shares outstanding as of August 10, 2026.
ArriVent BioPharma, Inc. (AVBP) dosed the first patient in the U.S. in the Phase 1 trial of ARR-002, a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate for ovarian and endometrial cancer. The trial evaluates safety, tolerability, efficacy and pharmacokinetics in advanced or metastatic ovarian or endometrial cancer. ARR-002 is the company’s second ADC to enter the clinic. In August 2026, ArriVent entered an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize ARR-002 in Greater China, defined as mainland China, Hong Kong, Macau and Taiwan; ArriVent retained all other rights. ARR-002 is also known as AV-P138-ADC and is described as a 2+2 format ADC with site-specific vcMMAE conjugation at a drug-to-antibody ratio of 4.
ArriVent BioPharma, Inc. (AVBP) common stock was sold by OrbiMed Private Investments VIII, LP (OPI VIII) and OrbiMed Asia Partners IV, L.P. (OAP IV): each partnership sold 75,683 shares on October 6, 2026, at $11.71 per share. The transactions reduced the reporting persons’ beneficial ownership of AVBP’s outstanding common stock by more than 1%.
As of the amendment, each partnership held 1,437,981 shares, approximately 2.9% of the class; OrbiMed Advisors LLC reported beneficial ownership of 2,875,962 shares, or 5.8%. Those percentages use 49,307,729 shares outstanding, based on ArriVent’s Form 10-Q filed August 12, 2026. The associated investors’ rights agreement provides demand, Form S-3, and piggyback registration rights subject to specified conditions.
ArriVent BioPharma, Inc. (AVBP) said its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). Median BICR PFS was 11.0 months with 240 mg, 8.4 months with 160 mg, and 9.5 months in the control arm; the 240 mg-versus-control comparison had a p-value of 0.0654.
Investigator-assessed median PFS was 11.1, 8.3 and 7.1 months for the 240 mg, 160 mg and control arms, respectively; confirmed objective response rates by BICR were 60%, 35% and 33%. Overall-survival data were not yet mature, although a trend toward improvement was observed. ArriVent reported no new safety signals and said FURVENT's safety profile was consistent with previous clinical studies.
ArriVent BioPharma, Inc. reported continued operating losses as it advances oncology programs, led by EGFR inhibitor firmonertinib and ADC ARR-217. For the six months ended June 30, 2026, the company recorded a net loss of $93.2 million, slightly improved from $95.8 million a year earlier. Research and development expenses were $80.0 million versus $89.0 million, reflecting lower early-stage program spend after a prior-year $40.0 million upfront payment, partly offset by higher Phase 3 trial and personnel costs. General and administrative expenses increased to $18.8 million from $11.4 million due to headcount and professional services.
Cash, cash equivalents and short-term investments totaled $373.1 million as of June 30, 2026, which the company states is sufficient to fund planned operations for at least twelve months from the financial statement issuance date. Liquidity was strengthened by $140.0 million in net proceeds from sales of 5,358,318 common shares under an at-the-market program, and an undrawn $75.0 million term loan facility. ArriVent also disclosed significant contingent milestone and royalty obligations under multiple licensing and collaboration agreements and outlined a new collaboration and license arrangement granting Allist rights to ARR-002 in Greater China.
ArriVent BioPharma, Inc. entered a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals, granting Allist an exclusive, sublicensable, royalty-bearing license to develop and commercialize ARR-002 in Greater China, while ArriVent retains rights elsewhere and a right to manufacture in the territory. ArriVent may receive up to $80.6 million in upfront and milestone payments, plus tiered royalties in the mid-single digit to low double-digit range on ARR-002 net sales in the licensed territory, with royalties payable for a defined patent, regulatory, or time-based royalty term.
For the quarter ended June 30, 2026, ArriVent reported a net loss of $49.9 million on operating expenses of $52.7 million, compared with a $31.4 million net loss a year earlier. For the first six months of 2026, net loss was $93.2 million, slightly improved from $95.8 million in the prior-year period as total operating expenses declined. The company ended June 30, 2026 with $154.7 million in cash and cash equivalents, $218.4 million in short-term investments, and total stockholders’ equity of $366.8 million, providing substantial capital to advance firmonertinib and its ADC pipeline, including ARR-217 and ARR-002.
BlackRock, Inc. reports beneficial ownership of common stock of Arrivent Biopharma Inc. on an amended Schedule 13G. BlackRock and certain of its business units collectively hold 3,182,080 shares, representing 6.8% of the common stock outstanding.
BlackRock reports sole voting power over 3,130,621 shares and sole dispositive power over 3,182,080 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Arrivent Biopharma’s outstanding common shares.
ArriVent BioPharma, Inc. director Parsey Merdad received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036.
The shares underlying this option vest on the first anniversary of the June 18, 2026 grant date, subject to his continued service through the vesting date. Following this award, he holds 13,562 derivative securities directly.
ArriVent BioPharma director Kristine Peterson received a new stock option grant. She was awarded a non-qualified option covering 13,562 shares of common stock at an exercise price of $31.74 per share. The option vests on the first anniversary of the grant date, contingent on her continued service, and expires on June 17, 2036. Following this grant, she holds 13,562 derivative securities directly from this award.
ArriVent BioPharma, Inc. director John Hohneker received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share, expire on June 17, 2036, and vest on the first anniversary of the June 18, 2026 grant date, subject to continued service.